Recombinant IL23A (Mirikizumab Biosimilar) antibody

Catalog No. ABIN7488152

The Mammalian Cells Monoclonal anti-IL23A (Mirikizumab Biosimilar) antibody is suitable to detect IL23A (Mirikizumab Biosimilar) in samples from Human. It has been validated for ELISA.

Quick Overview for Recombinant IL23A (Mirikizumab Biosimilar) antibody (ABIN7488152)

Target: IL23A (Mirikizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This IL23A (Mirikizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-IL23A (Mirikizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Mirikizumab Biosimilar - Anti-IL23A mAb

Characteristics: Antibody Type: IgG4-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG4 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL23A (Mirikizumab Biosimilar)

Target: IL23A (Mirikizumab Biosimilar)

Target Type: Biosimilar

Background: LY-3074828
Mirikizumab is a humanized IgG4 monoclonal antibody that targets p19 subunit of IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn's disease (CD).

CAS-No: 1884201-71-1